EFTA01388118.pdf

From: Martin Zeman Sent: 7/24/2018 10:04:OS AM To: Stewart 0ldfield I Subject: RE: Launch Package: LinkSPINE $20M Private Placement (I) Classification: For internal use only Hmm. Jeffrey wasn't there... From: Stewart Oldfield Sent: Tuesday, July 24, 2018 10:01 AM To: Martin Zeman < Subject: RE: Launch Package: LinkSPINE $20M Private Placement Should I be surprised that I never heard about a meeting with my client at Dan's club??? From: Martin Zeman Sent: Tuesday, July 24, 2018 9:32 AM To: 'Paul Barrett )I ‹ Cc: Stewart Oldfield < >; Zack Tax >; Oliver Rothauser Subject: Launch Package: LinkSPINE $20M Private Placement Paul, This comes from our "private markets desk" — you met Oliver end of last year around lunch at Dan's club. Do you think Jeffrey would be interested? A $20 million private placement we are engaged on with our Investment Bank for a medical device company, LinkSPINE. LinkSPINE is targeting the outpatient market for spinal surgery with two products: 1) a novel, minimally invasive midline kit providing physicians procedural flexibility and efficiency which is specifically designed for use in outpatient facilities 2) TargetLlNK, a chip-based navigation software platform to facilitate the placement of screws while reducing radiation exposure to physicians and patients during surgery by 80-90%. The Company's consumable products are already FDA approved for commercial use and the Company expects their TargetLlNK product to receive FDA approval in the next 9 months. The Company has been incubated by the Link Group, a German based orthopedics firm with an established track record of successfully bringing medical device products to market. To date, they have invested $25 million into LinkSPINE. Use of proceeds for this round are being allocated to build a robust commercial sales and marketing infrastructure for their products. Attached you can find a brief teaser on the Company and if you are interested in leaming more we are able to facilitate an introductory call with our Investment Bank to take a deeper dive into both the products and spinal surgery market. Nlartin CONFIDENTIAL - PURSUANT TO FED. R. GRIM. P. 6(e) DB-SDNY-0091499 CONFIDENTIAL SDNY_GM_00237683 EFTA01388118